Refutes Claims of "Speculative Stock Manipulation"

Clarifies Contract Size Amid Controversy

Samchundang Pharmaceutical, a large-cap company listed on the KOSDAQ market, saw its shares plummet, while the company announced plans to take strong legal action against allegations of stock price manipulation that have surfaced online.


Samchundang Pharmaceutical Headquarters. Samchundang Pharmaceutical

Samchundang Pharmaceutical Headquarters. Samchundang Pharmaceutical

View original image

On March 31, Samchundang Pharmaceutical announced on its official website that "a particular blogger is causing market confusion with baseless posts such as 'operation stock' and 'blatant stock price manipulation,'" and stated the company would file complaints for defamation and obstruction of business. Blogger A raised suspicions about Samchundang Pharmaceutical's stock price movements in a post on March 30, referencing the company's main business activities and contract processes.


The company also objected to the analysis of a specific analyst. "We have strongly protested to the analyst who distributed a post suggesting that additional clinical trials are necessary for generic drug registration," the company said, emphasizing that "we will consider legal action against any posts made without factual verification."


Samchundang Pharmaceutical's share price had previously surged rapidly due to high expectations for its oral insulin platform and development of GLP-1 (glucagon-like peptide-1) class obesity and diabetes treatments. At the beginning of this year, the company's market capitalization was around 5 trillion won, but it soared to the 20 trillion won range in a short period.


However, investment sentiment deteriorated sharply as the contract details disclosed the previous day were seen as falling short of market expectations. Although the company announced that it had signed an exclusive contract related to oral semaglutide in the U.S. market, there was criticism that the disclosed contract value was smaller than anticipated.


Samchundang Pharmaceutical explained, "The 150 billion won reported as the contract amount is only a milestone payment," adding, "Actual sales are expected to reach approximately 15 trillion won during the contract period by the partner company, and Samchundang will receive 90% of the net profit from these sales."


Despite the company’s decision to file a complaint, Blogger A responded with an additional post, saying, "If a company can collapse over such a post, that is an even bigger problem," and added, "If you report me, I will go all the way."



Meanwhile, Samchundang Pharmaceutical, which had entered the so-called "Emperor Stock" category by closing at 1,115,000 won on March 25, climbed to 1,184,000 won the previous day, but then plunged 29.98% in a single day to close at 829,000 won.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing